Motus GI Holdings logo
Motus GI Holdings MOTS
report update icon

Quarterly report 2024-Q1
added 05-16-2026

Motus GI Holdings Balance Sheet 2023-2011 | MOTS

Brief balance sheet overview of Motus GI Holdings

The comparison uses five available annual reports from the 2019–2023 interval.

Assets declined from $32.3 million to $7.2 million, or -77.6%. The contraction calls for context such as disposals, restructuring or weaker operations.

Asset growth of -77.6% came with a -67.4% rise in liabilities. Financial leverage became more prominent.

The equity ratio is 37.2% versus 56.8% five periods ago. Capitalization remains workable.

The balance sheet holds more cash than interest-bearing debt; net debt is -$3.5 million, indicating minimal leverage.

Cash represents 68.6% of assets versus 63.6% initially, showing how the immediate liquidity reserve changed.

Retained earnings are negative at -$154.2 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.

Overall assessment

Motus GI Holdings has a workable but not unconditionally strong balance sheet. Resilience depends on sustained earnings and liability control.

Annual Balance Sheet Motus GI Holdings

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-3.55 M -9.21 M -15.1 M -12.6 M -12.5 M -18 M -6.94 M -11.6 M 3.45 M - - - -

Long Term Debt

1.24 M 4.59 M 7.12 M 7.98 M 7.75 M - - - 4.74 M - - - -

Long Term Debt Current

169 K 245 K 307 K 238 K 321 K - - - - - - - -

Total Non Current Liabilities

- - - 2.16 M 2.58 M 2.04 M 1.66 M 1.41 M 4.74 M - - - -

Total Current Liabilities

3.27 M 4.8 M 3.33 M 10.6 M 11.3 M 2.39 M 1.98 M - - - - - -

Total Liabilities

4.54 M 14.7 M 16.4 M 12.8 M 13.9 M 4.44 M 3.64 M 2.16 M 5.44 M - - - -

Retained Earnings

-154 M -141 M -123 M -104 M -84.5 M -61.4 M -39.1 M -25.9 M -17.9 M - - - -

Total Assets

7.22 M 17.6 M 26.1 M 24.1 M 32.3 M 23 M 9.17 M 12.2 M 1.72 M - - - -

Cash and Cash Equivalents

4.96 M 14 M 22.6 M 20.8 M 20.5 M 18 M 6.94 M - - - - - -

Book Value

2.69 M 2.98 M 9.66 M 11.3 M 18.3 M 18.5 M 5.52 M 10 M -3.72 M - - - -

Total Shareholders Equity

2.69 M 2.98 M 9.66 M 11.3 M 18.3 M 18.5 M 5.52 M - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Motus GI Holdings

2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

669 K 1.24 M 2.47 M 3.2 M 3.9 M 4.59 M 5.25 M 5.89 M 6.52 M 7.12 M 4.61 M 8 M 8 M 7.98 M 7.98 M 7.98 M 7.77 M 7.75 M 748 K 620 K 683 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

4 M 4.54 M 11 M 12.7 M 13.3 M 14.7 M 16.6 M 16.1 M 15.8 M 16.4 M 13.3 M 12.6 M 12.4 M 12.8 M 12.7 M 12.5 M 13.4 M 13.9 M 6.18 M 5.71 M 5.24 M 4.44 M 4.46 M 3.36 M 3.36 M 3.64 M 3.64 M 3.64 M 3.64 M - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-156 M -154 M -151 M -149 M -146 M -141 M -138 M -133 M -128 M -123 M -118 M -113 M -108 M -104 M -99.3 M -95.4 M -91 M -84.5 M -78.5 M -73.3 M -67.7 M -61.4 M -55.8 M -50.6 M -46.4 M -39.1 M -39.1 M -39.1 M -39.1 M - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

7.07 M 7.22 M 8.49 M 11.7 M 12.2 M 17.6 M 17.4 M 20.1 M 24.4 M 26.1 M 27.1 M 30.2 M 31.9 M 24.1 M 27.7 M 21.4 M 26 M 32.3 M 29.8 M 13.8 M 18.3 M 23 M 13.9 M 16.8 M 20.5 M 9.17 M 9.17 M 9.17 M 9.17 M - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

4.94 M 4.96 M 5.72 M 8.52 M 8.65 M 14 M 13.3 M 15.8 M 20.3 M 22.6 M 23.7 M 26.4 M 27.7 M 20.8 M 23.7 M 17.1 M 21.5 M 20.5 M 15.7 M 7.85 M 10.2 M 18 M 6.89 M 5.07 M 18.6 M 6.94 M 6.94 M 6.94 M 6.94 M 11.7 M - - - - - - - - - - - - - - - - - - - - - - -

Book Value

3.07 M 2.69 M -2.48 M -963 K -1.08 M 2.98 M 762 K 3.97 M 8.61 M 9.66 M 13.8 M 17.6 M 19.4 M 11.3 M 15 M 8.89 M 12.6 M 18.3 M 23.6 M 8.09 M 13.1 M 18.5 M 9.44 M 13.5 M 17.2 M 5.52 M 5.52 M 5.52 M 5.52 M - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

3.07 M 2.69 M -2.48 M -963 K -1.08 M 2.98 M 762 K 3.97 M 8.61 M 9.66 M 13.8 M 17.6 M 19.4 M 11.3 M 15 M 8.89 M 12.6 M 18.3 M 23.6 M 8.09 M 13.1 M 18.5 M 9.44 M 13.5 M 17.2 M 5.52 M 5.52 M 5.52 M 5.52 M 10 M - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Motus GI Holdings, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Diagnostics research

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Biomerica Biomerica
BMRA
$ 2.14 1.9 % $ 4.92 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.17 0.88 % $ 6.37 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Co-Diagnostics Co-Diagnostics
CODX
$ 1.21 0.79 % $ 1.61 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 14.3 0.7 % $ 486 M israelIsrael
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 242.76 0.02 % $ 26.9 B usaUSA
Celcuity Celcuity
CELC
$ 88.44 3.05 % $ 4.14 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Charles River Laboratories International Charles River Laboratories International
CRL
$ 291.5 0.16 % $ 14.4 B usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 6.77 1.18 % $ 27 M israelIsrael
DexCom DexCom
DXCM
$ 90.82 1.71 % $ 35.4 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 398.58 0.64 % $ 28.8 B schweizSchweiz
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 3.16 1.92 % $ 293 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 5.01 4.53 % $ 3.94 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 18.05 7.31 % $ 2.31 B usaUSA
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
National Research Corporation National Research Corporation
NRC
$ 21.85 0.27 % $ 489 M usaUSA
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.48 1.11 % $ 113 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.4 0.32 % $ 420 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 170.02 0.18 % $ 13.3 B irlandaIrlanda
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.45 2.11 % $ 6.41 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 261.75 0.05 % $ 45 B usaUSA
Surmodics Surmodics
SRDX
- - $ 608 M usaUSA